# ALBIREO PHARMA, INC.

ALBIREO PHARMA, INC. is a company headquartered in Boston, MA, United States.

## Company overview

- **Legal name:** ALBIREO PHARMA, INC.
- **Former names in filing history:** Biodel Inc (2005-03-28 to 2016-11-02)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Boston, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001322505

## About

ALBIREO PHARMA, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001322505, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2022-03-01, it reported annual revenue of USD 40,579,000; net income of USD -34,030,000; total assets of USD 302,051,000 for the fiscal period ended 2021-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $40.6M (USD 40,579,000)
- **Net income:** -$34.0M (USD -34,030,000)
- **Total assets:** $302.1M (USD 302,051,000)
- **Cash and equivalents:** $248.1M (USD 248,107,000)
- **Operating cash flow:** -$107.6M (USD -107,559,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $8.3M (USD 8,308,000)
- **Net income:** -$107.6M (USD -107,633,000)
- **Total assets:** $285.6M (USD 285,607,000)
- **Cash and equivalents:** $251.3M (USD 251,272,000)
- **Operating cash flow:** -$101.0M (USD -101,029,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $9.6M (USD 9,636,000)
- **Net income:** -$62.7M (USD -62,717,000)
- **Total assets:** $165.1M (USD 165,069,000)
- **Cash and equivalents:** $131.8M (USD 131,843,000)
- **Operating cash flow:** -$52.9M (USD -52,919,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $12.7M (USD 12,740,000)
- **Net income:** -$46.1M (USD -46,111,000)
- **Total assets:** $185.5M (USD 185,466,000)
- **Cash and equivalents:** $163.9M (USD 163,885,000)
- **Operating cash flow:** -$26.8M (USD -26,802,000)

## Recent SEC filings

- Form 8-K — filed 2023-03-02 — period 2023-03-02 — FORM 8-K
- Form SC 13G — filed 2023-03-02
- Form SC 13G — filed 2023-02-27
- Form SC 13G — filed 2023-02-24 — SC 13G
- Form 8-K — filed 2023-02-14 — period 2023-02-14 — FORM 8-K
- Form SC 13G — filed 2023-01-23
- Form 8-K — filed 2023-01-09 — period 2023-01-08 — FORM 8-K
- Form 8-K — filed 2022-12-06 — period 2022-12-01 — FORM 8-K
- Form 10-Q — filed 2022-11-08 — period 2022-09-30 — 10-Q
- Form 8-K — filed 2022-11-08 — period 2022-11-08 — FORM 8-K
- Form 8-K — filed 2022-10-11 — period 2022-10-11 — FORM 8-K
- Form SC 13G — filed 2022-10-03

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/albireo-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology